- Home
- CHGG vs XGN Comparison
CHGG vs XGN Comparison
Compare CHGG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHGG | XGN |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 110.7M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CHGG | XGN |
|---|---|---|
| Price | $1.08 | $4.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | ★ 1.3M | 243.7K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $376,908,000.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $2.59 |
| 52 Week High | $1.87 | $12.23 |
Technical Indicators
Market Signals| Indicator | CHGG | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 56.84 |
| Support Level | $0.88 | $4.11 |
| Resistance Level | $1.20 | $4.85 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 46.70 | 66.11 |
Price Performance
Historical ComparisonAbout CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Chegg Skilling; and Academic Services, which derives maximum revenue. Geographically, it derives in United States and International.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.